CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: Results of a study of expression levels of 23 genes

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4619-4628

  Kowalczuk, Oksana ^a   Burzykowski, Tomasz ^a,b   Niklinska, Wieslawa Ewa ^a   Kozlowski, Miroslaw ^a   Chyczewski, Lech ^a   Niklinski, Jacek ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

CXCL5; Molecular markers; Non small cell lungcancer; Prognosis

Indexed keywords

ALPHA5 INTEGRIN; ARF GAP DOMAIN AND FG REPEAT CONTAINING PROTEIN 1; BETA1 INTEGRIN; BETA3 INTEGRIN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHOLINE KINASE; CHOLINE KINASE ALPHA; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HYPOCALCIN; HYPOCALCIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; SOLUTE CARRIER FAMILY MEMBER 2 MEMBER 1 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CXCL5 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINE CXCL5; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84902960994     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1605-x     Document Type: Article

References (44)

1. Strauss GM. Management of early-stage lung cancer: past, present, and future adjuvant trials. Oncology (Williston Park). 2006;13:1651-63.
2. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-56. (Pubitemid 41746029)
3. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102:464-74.
4. Provenzano M, Mocellin S. Complementary techniques: validation of gene expression data by quantitative real time PCR. Adv Exp Med Biol. 2007;593:66-73.
5. Goulter AB, Harmer DW, Clark KL. Evaluation of low density array technology for quantitative parallelmeasurement of multiple genes in human tissue. BMC Genomics. 2006;7:34.
6. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816-24.
7. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006;66:7466-72. (Pubitemid 44289200)
8. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006;3:e467.
9. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol. 2004;22:811-9. (Pubitemid 41103592)
10. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small lung cancer: a retrospective study. Lancet Oncol. 2007;8:889-97. (Pubitemid 47488053)
11. McClelland MR, Carskadon SL, Zhao L, et al. Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol. 2007;36:343-50. (Pubitemid 46365285)
12. White ES, Flaherty KR, Carskadon S, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003;9:853-60. (Pubitemid 36182624)
13. Minamiya Y, Saito H, Takahashi N, et al. Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer. 2010;68:466-71.
14. Suzuki M, Mohamed S, Nakajima K, et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with unfavorable prognosis. Int J Oncol. 2008;33:113-9.
15. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst. 2007;99:1257-69. (Pubitemid 47299904)
16. Soria JC, Moon C, Kemp BL, et al. Lack of interleikin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2003;9:1785-91. (Pubitemid 36554605)
17. Dingemans A-M, van den Boogaart V, Vosse BA, et al. Integrin expression profiling identifies integrin alpha 5 and beta 1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer. 2010;9:152-60.
18. T method. Nat Protoc. 2008;3:1101-8.
19. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
20. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-6. (Pubitemid 26342716)
21. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester, UK: Wiley; 2008.
22. Dmitrienko A, Tamhane AC, Bretz F. Multiple testing problems in pharmaceutical statistics. Chapman & Hall/CRC: Boca Raton; 2010.
23. Vandercappellen J, Van Damme J, Srtuyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267:226-44.
24. Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 2007;26:453-67. (Pubitemid 350115099)
25. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Bio Techniques. 2008;44:619-26. (Pubitemid 351656280)
26. Walz A, Burgener R, Car B, et al. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 1991;174:1355-62.
27. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res. 2011;317:685-90.
28. Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest. 1998;102:465-72. (Pubitemid 28376148)
29. Sun H, Chung WC, Ryu SH, et al. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila). 2008;1:316-28.
30. Begley LA, Kasina S, Mehra R, et al. CXCL5 promotes prostate cancer progression. Neoplasia. 2008;10:244-54. (Pubitemid 351328584)
31. Li A, King J, Moro A, et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol. 2011;178:1340-9.
32. Kawamura M, Toiyama Y, Tanaka K, et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer. 2012;48:2244-51.
33. Frick VO, Rubie C, Wagner M, et al. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology. 2008;8:488-97.
34. Rubie C, Frick VO, Wagner M, et al. ELR + CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer. 2008;8:178.
35. Bièche I, Chavey C, Andrieu C, et al. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer. 2007;14:1039-52. (Pubitemid 351252435)
36. Furuya M, Suyama T, Usui H, et al. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol. 2007;38:1676-87. (Pubitemid 47589091)
37. Park JY, Park KH, Bang S, et al. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol. 2007;133:835-40. (Pubitemid 350218909)
38. Okabe H, Beppu T, Ueda M, et al. Identification of CXCL5/ENA-78 as a factor involved in the interaction between cholangiocarcinoma cells and cancer-associated fibroblasts. Int J Cancer. 2012;131:2234-41.
39. Speetjens FM, Kuppen PJ, Sandel MH, et al. Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res. 2008;14:2276-84. (Pubitemid 351551058)
40. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res. 2009;15:284-90.
41. Skrzypski M. Quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR) in translational oncology: lung cancer perspective. Lung Cancer. 2008;59:147-54.
42. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Eng J Med. 2006;355:570-80. (Pubitemid 44200650)
43. Singhal S, Miller D, Ramalingam S, et al. Gene expression profiling of non-small cell lung cancer. Lung Cancer. 2008;60:313-24.
44. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non-small-cell lung cancer. J Clin Oncol. 2007;35:5562-9.